liver diseases

CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.

Antipyrine (Phenazone), an antipyretic and analgesic, has been given as ear drops and by mouth. Antipyrine is frequently used to test the effects of other diseases or drugs on drug-metabolizing enzymes in the liver.

5-Amino-3H-imidazole-4-Carboxamide (AICA) is an imidazole derivative and a metabolite of the antineoplastic agents BIC and DIC. It serves as a condensation agent in the preparation of nucleosides and nucleotides, and when compounded with orotic acid, it is used to treat liver diseases.

1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.

Silymarin (Silybin B) (Silybin B) is a polyphenolic flavonoid that extracts from the milk thistle or seeds of Silybum marianum. It is used in the prevention and treatment of liver diseases.

S-Adenosyl-L-methionine disulfate tosylate is a methyl donor with oral activity. S-Adenosyl-L-methionine disulfate tosylate is a dietary supplement with effective antidepressant and pain-relieving effects. S-Adenosyl-L-methionine disulfate tosylate also has anti-proliferative, pro-apoptotic and anti-metastatic effects in cancer. S-Adenosyl-L-methionine can be used in the research of liver diseases and osteoarthritis.

LY 43578 is an orally active aromatase inhibitor. LY43578 could inhibit O-demethylation of P-450-dependent p-nitroanisole and N-demethylation of ethylmorphine (IC50 of 0.3 and 5 μm, respectively) in rat liver microsomes. LY 43578 can be used to study neurological and cardiovascular diseases.

CZC-25146 (CHEMBL2397014) is an effective, specific and metabolically stable LRRK2 inhibitor with IC50 of 4.76 6.87 nM for wild-type LRRK2(Leucine-rich repeat kinase-2) and G2019S LRRK2, respectively.

2-Iodohippuric Acid can be used to measure renal clearance for renal function studies, and for the diagnosis of certain diseases, such as liver and kidney disease. In addition, it is used in the synthesis of certain drugs.

Huangjiangsu A has hepatoprotective potential against H2O2-induced cytotoxicity and ROS generation and could be promising as potential therapeutic agents for liver diseases. Huangjiangsu A is isolated from D. villosa.

ALG-055009, a thyroid hormone receptor β (THR-β) agonist, exhibits an EC50 of 0.063 μM. It has been shown to reduce total cholesterol levels in rats fed a high-fat diet. ALG-055009 is used in the study of fatty liver diseases associated with metabolic dysfunction.

DGAT2-IN-3 (compound 9) is an inhibitor of DGAT2 with an IC50 value of 0.4 nM. It is utilized in research related to fatty liver disease, diabetes, and cardiovascular diseases.

KR-40795 is an effective inhibitor of ATX (autotaxin) with an IC50 of 0.13 μM. This compound plays a crucial role in liver diseases.

1,2,3,4,7,8,9-Heptachlorodibenzofuran (1,2,3,4,7,8,9-HpCDF) is a chemical compound known for inducing the expression of CYP1A1 and CYP1B1 genes in human peripheral blood lymphocytes, while also enhancing the expression of the aromatic hydrocarbon receptor repressor (AhRR). In isolated human peripheral blood lymphocytes, it boosts ethoxyresorufin-O-deethylase (EROD) activity—a marker for CYP1A1 activity—in a concentration-dependent manner. Additionally, 1,2,3,4,7,8,9-HpCDF exhibits immunosuppressive properties, reducing the number of plaque-forming cells in mouse spleens and increasing aromatic hydrocarbon hydroxylase (AHH) activity in the liver microsomes of mice injected with sheep red blood cells. This compound is pertinent to research in the fields of immunology, metabolic diseases, and environmental toxicology.

BE2647 is a selective inhibitor of the mitochondrial pyruvate carrier (MPC), with an EC50 of 70 nM. It exhibits good metabolic stability in mouse liver microsomes. BE2647 can be utilized in research related to metabolic diseases, metabolic-associated steatotic liver disease (MASLD), or metabolic-associated steatohepatitis (MASH).

5-HT2B antagonist-2 (Compound 19c) is a 5HT2B receptor antagonist with an IC50 of 1.09 nM. It effectively downregulates the expression of fibrosis-related genes α-SMA, Timp1, Col1a1, and Col3a1, significantly reducing cellulose deposition. In a CCl4-induced liver fibrosis mouse model, it decreases the fibrotic area and inhibits the progression of fibrosis. This compound is useful for research into immune-inflammatory related diseases, particularly pulmonary fibrosis.

Galectin-3-IN-6 (Compound 12) is an orally active galectin-3 (Gal-3) inhibitor, with an IC50 of 12 nM and a Kd of 13 nM for Gal-3. In a CCl4-induced mouse model of acute liver injury and fibrosis, Galectin-3-IN-6 significantly reduces fibrosis markers collagen-1 and α-smooth muscle actin (αSMA) by 64% and 71%, respectively, demonstrating notable anti-fibrotic activity. Galectin-3-IN-6 is applicable for research in fibrosis-related diseases, cancer, and cardiovascular disorders.

MSRV-IN-1 (Compound M3) is an inhibitor targeting aquatic rhabdoviruses, including MSRV, SVCV, and IHNV, with IC50 values of 0.92 μM, 2.92 μM, and 2.78 μM, respectively. Instead of acting directly on virus particles, MSRV-IN-1 disrupts the replication environment by altering the virus-induced S-phase cell cycle arrest, inhibiting viral replication. Administered via intraperitoneal injection at a dose of 20 mg/kg, MSRV-IN-1 significantly improves the survival rate of MSRV-infected largemouth bass by 35.98% and reduces viral load in the liver, spleen, and kidneys. MSRV-IN-1 is applicable in research on rhabdovirus-associated diseases in aquaculture.

20-Hydroxyvitamin D3 (20(OH)D3) is a hydroxy metabolite of vitamin D3. It functions as a ligand for the vitamin D receptor (VDR), aryl hydrocarbon receptor (AhR), liver X receptor (LXR), and retinoic acid receptor-related orphan receptor (ROR). 20-Hydroxyvitamin D3 inhibits cell proliferation and induces differentiation. It is applicable in research on inflammatory and autoimmune diseases.

CypB-IN-1 (Compound 11) is an inhibitor of cyclophilin B (CypB) with a dissociation constant (Kd) of 12 nM. It is used in research related to metabolic dysfunction-associated steatohepatitis (MASH) and the liver fibrosis diseases it induces.

SSAO inhibitor-1 is a compound that acts as an inhibitor of semicarbazide-sensitive amine oxidase (SSAO). It exhibits anti-inflammatory properties and is commonly employed in research pertaining to liver diseases.

CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.

JAK3 BTK-IN-6 is a potent dual inhibitor of BTK (IC50: 0.6 nM) and JAK3 (IC50: 0.4 nM).JAK3 BTK-IN-6 exhibits good metabolic stability in human liver microsomes.JAK3 BTK-IN-6 can be used to study blood and immune diseases.

Omesdafexor is an FXR agonist that can be used to study diseases caused by liver disease or metabolic inflammation.